Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.33 |
| ▸ | RORC | P51449 | 6/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | KRAS | P01116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093802 | 0.84 | NR3C1 (0.37) | NR3C1RORCDGAT2IDO1BRD4 | |
| SCHEMBL30861007 | 0.81 | BRD9 (0.37) | NR3C1RORCDGAT2BRD4ATR | |
| SCHEMBL31093895 | 0.74 | ATR (0.36) | NR3C1RORCDGAT2IDO1ATR | |
| SCHEMBL31093724 | 0.69 | DHPS (0.39) | S1PR3IDO1 | |
| SCHEMBL27227929 | 0.69 | RXRA (0.38) | NR3C1DGAT2CYP4F2CYP4A11 | |
| SCHEMBL31093693 | 0.67 | ATR (0.35) | NR3C1RORCS1PR3BRAFATR | |
| SCHEMBL15208344 | 0.67 | HTR2C (0.43) | DGAT2ATRCYP4F2CYP4A11KRAS | |
| SCHEMBL25420259 | 0.66 | ATR (0.35) | RORCDGAT2BRAFATRCYP4F2 | |
| SCHEMBL30950290 | 0.66 | CYP4F2 (0.41) | DGAT2CYP4F2CYP4A11 | |
| SCHEMBL26913256 | 0.65 | FGFR1 (0.37) | BRAFKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4673436-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024179948-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078122-A1 | INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS | PKN3, PKMYT1, IP6K3 | NR3C1 1638/4885RORC 2507/4885S1PR3 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.